




















## FINANCIAL HIGHLIGHTS



### PRODUCT PERFORMANCE HIGHLIGHTS \$M



<sup>1</sup> Growth rates represent underlying performance, which shows growth at constant exchange rates (CER) by excluding the effects of exchange rate movements. Underlying CER growth is calculated by retranslating the current year performance at the previous year's exchange rates and adjusting for other exchange effects, including hedging.

<sup>2</sup> Free cash flow represents net cash flows before financing activities, and is calculated as: net cash inflow before financing activities, adjusted for acquisitions of businesses, movements in short term investments and fixed deposits and disposal of intangible assets.

### DIVIDEND FOR 2006

	\$	Pence	SEK	Payment date
First interim dividend	0.49	26.6	3.60	18 September 2006
Second interim dividend	1.23	63.0	8.60	19 March 2007
<b>Total</b>	<b>1.72</b>	<b>89.6</b>	<b>12.20</b>	

## STRATEGY

### **ASTRAZENECA IS A SUCCESSFUL GLOBAL RESEARCH-BASED PRESCRIPTION PHARMACEUTICAL COMPANY, AND OUR GOAL IS TO MAKE A DIFFERENCE IN THE LIVES OF PATIENTS AND CREATE VALUE FOR OUR SHAREHOLDERS AND WIDER SOCIETY, THROUGH THE DELIVERY OF INNOVATIVE MEDICINES IN IMPORTANT AREAS OF HEALTHCARE.**

#### OUR STRATEGY

Our strategy for ensuring that we continue to make our best contribution to healthcare and deliver sustained, industry-leading, responsibly managed growth centres on three key priorities:

- > Strengthening our pipeline of new medicines, from our own research laboratories and by accessing scientific innovation that resides outside AstraZeneca.
- > Delivering the full potential of all our marketed medicines, through rigorous life-cycle management and excellent customer support.
- > Challenging our cost structure to make room for the further investment necessary in these critical activities.

Across all of our activities, we will continue to work closely with all our stakeholders to provide medicines that meet patient needs and add value for society, within the scope of our existing therapy areas and beyond.

We have a clear set of objectives for delivering this strategy. Through the professionalism and commitment of our people, we are determined to deliver a performance that will place AstraZeneca among the best in the industry.

#### OUR OBJECTIVES

The objectives that we have identified as critical drivers of success in delivering our strategy are focused on four core areas:

##### Patients

- > Gaining and using insight effectively by:
  - Working closely with patients and their healthcare providers to understand what they need and what they value.
  - Incorporating this insight into all aspects of our business decision-making (from discovery to marketing and beyond) to ensure we remain focused on those healthcare needs that are most relevant. This includes targeting our medicines at those patients for whom they are most effective.
- > Providing superior customer support through:
  - Innovative practices that enable patients and their caregivers to better understand their disease and treatment options, and to get the medicines they need and the best possible value from them.

##### Products

- > Strengthening our research platform and pipeline to deliver a flow of innovative, new products by:
  - Improving further the quality, speed and productivity of our internal discovery and development through the use of leading-edge science, alongside a continued focus on driving effective risk management, decision-making and efficiency across all our processes.
  - Accessing attractive external opportunities to enhance our internal innovation through partnerships, alliances and acquisitions that further strengthen our pipeline of new products.
  - Making a strategic move into biologicals to build a major presence in the fast-growing biopharmaceuticals sector.

- > Realising the full potential of our marketed products by:

Actively managing the lifecycles of each of our brands to leverage the full therapeutic and commercial potential of our range.

Driving high standards of sales force effectiveness and marketing excellence.

Building on our leadership positions in existing markets and expanding our presence in important emerging ones.

##### People

- > Getting the best from our global workforce by:
  - Providing effective leadership with clear objectives and accountabilities.
  - Effectively managing and developing all our talent.
  - Promoting a culture of diversity and inclusion in which people feel valued and rewarded for their individual and team contribution.
- > Making every interaction count by:
  - Ensuring people understand that how we do business is just as important as what we do, and that everyone has a responsibility for integrating our core values into their everyday business activity.

##### Performance

- > Delivering a performance that will place us among the best in the industry, with a reputation as one of the most forward-thinking and responsible companies by:
  - Meeting our promises in all aspects of our business, focusing on our core priorities and on how we deliver them.
  - Effectively managing the opportunities and risks associated with all our business activities.
  - Rigorously challenging our cost structure to improve cost-effectiveness and operational excellence.
  - Ensuring a continuous focus on corporate governance and compliance.